Welcome to our dedicated page for PERIMETER MED IMAGING AI news (Ticker: PYNKF), a resource for investors and traders seeking the latest updates and insights on PERIMETER MED IMAGING AI stock.
Perimeter Medical Imaging AI, Inc. (PYNKF) is a commercial-stage medical technology company focused on transforming cancer surgery. Headquartered in Toronto, Canada, and Dallas, Texas, the company provides ultra-high-resolution, real-time, advanced imaging tools to address critical medical needs. With FDA-cleared Perimeter S-Series OCT system for cellular-level visualization and investigational Perimeter B-Series OCT with ImgAssist AI, Perimeter is at the forefront of utilizing artificial intelligence to enhance surgical outcomes and patient care.
Perimeter Medical Imaging AI, Inc. (TSXV: PINK, OTC: PYNKF) announced its participation at the 24th Annual Meeting of the American Society of Breast Surgeons (ASBrS) from April 26-30, 2023, in Boston, MA. The company will host an educational symposium titled "ACT IN THE MOMENT: OCT adds real-time clarity on margin status," featuring prominent breast surgeons who will share their experiences utilizing the Perimeter S-Series Optical Coherence Tomography (OCT) technology. This device provides real-time imaging to assist surgeons during procedures. Perimeter will also offer live demonstrations at Booth #923, showcasing the OCT system's capabilities in visualizing tissue margins at a cellular level. The event underscores Perimeter's commitment to advancing breast cancer surgery technology.
Perimeter Medical Imaging AI, Inc. (OTC: PYNKF) announced the first commercial placement of its Perimeter S-Series OCT system in Utah on April 25, 2023. This FDA-cleared imaging tool, launched in 2021, enhances cancer surgery with real-time, cross-sectional visualization of excised tissues. Dr. Jennifer J. Tittensor, a breast surgeon, will utilize the system to improve margin assessments during surgeries. Perimeter's CEO, Jeremy Sobotta, noted growing interest from surgeons, indicating a positive sales momentum. The company is also advancing its next-generation Perimeter B-Series OCT with ImgAssist AI, supported by a grant of up to $7.4 million from the Cancer Prevention and Research Institute of Texas, highlighting its commitment to innovation in oncological surgery.
Perimeter Medical Imaging AI, Inc. (TSXV: PINK, OTC: PYNKF) announced its participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25-26, 2023, in Toronto. The company, focused on revolutionizing cancer surgery through advanced imaging technologies, aims to address significant unmet medical needs.
Key details include:
- Company Presentation: April 26, 2023, from 11:00-11:30 AM ET.
- Webcast Link: Register here.
- Presenter: Jeremy Sobotta, CEO.
Perimeter aims to enhance surgical outcomes with its Perimeter S-Series OCT system and investigates the Perimeter B-Series OCT with cutting-edge AI technology, supported by a US$7.4 million grant for clinical trials.
Perimeter Medical Imaging AI, Inc. (TSXV: PINK, OTC: PYNKF) reported its financial results for the year ended December 31, 2022, revealing a net loss of $9.9 million, down from $13.3 million in 2021. Operating expenses rose to $16.6 million from $12.9 million, with cash used in operations at $11.9 million. The company successfully completed a private placement generating C$48.7 million and doubled its commercial installed base of the Perimeter S-Series OCT in Q4 2022. All eight clinical trial sites for the B-Series OCT system were activated, with expansion authorized. The company anticipates completion of patient enrollment in its trial by the end of 2023.
Additionally, the company aims to enhance the surgical outcomes during breast conservation surgery through its innovative imaging technology.
Perimeter Medical Imaging AI, Inc. (PYNKF) will announce its financial and operational results for the year ending December 31, 2022, on April 11, 2023, after U.S. market close. The company aims to transform cancer surgery through advanced imaging technology. The conference call is scheduled for the same day at 5 PM ET, featuring CEO Jeremy Sobotta. Investors can join via a dial-in number or a webcast. The Perimeter S-Series OCT system is FDA-cleared for real-time visualization of excised tissues, while the B-Series OCT is undergoing pivotal trials with funding support of up to $7.4 million from the Cancer Prevention and Research Institute of Texas.
Perimeter Medical Imaging AI has published a new white paper on the efficacy of its Perimeter S-Series OCT technology in breast conserving surgeries for ductal carcinoma in situ. The paper, authored by Dr. Amelia Tower, outlines three case studies where the technology enabled real-time margin visualization, allowing for intraoperative decisions that eliminated the need for additional surgeries. CEO Jeremy Sobotta highlighted the technology's potential to improve patient outcomes and reduce healthcare costs. The white paper was also presented at the SSO 2023 International Conference, showcasing Perimeter's commitment to advancing cancer surgery through innovative imaging tools.
FAQ
What is the current stock price of PERIMETER MED IMAGING AI (PYNKF)?
What is the market cap of PERIMETER MED IMAGING AI (PYNKF)?
What is Perimeter Medical Imaging AI, Inc. focused on?
Where is Perimeter Medical Imaging AI, Inc. headquartered?
What products does Perimeter Medical Imaging AI, Inc. offer?
What sets Perimeter Medical Imaging AI, Inc. apart in the medical technology industry?
How is Perimeter Medical Imaging AI, Inc. contributing to cancer surgery advancements?
What is the significance of Perimeter Medical Imaging AI, Inc.'s ticker symbol 'PINK'?
Where can I find more information about Perimeter Medical Imaging AI, Inc.'s disclosures and products?
What recent achievements has Perimeter Medical Imaging AI, Inc. showcased?
How can investors stay informed about Perimeter Medical Imaging AI, Inc.'s updates and performance?
What partnerships or collaborations has Perimeter Medical Imaging AI, Inc. established?
